3 UK dividend shares I’d buy today

first_img3 UK dividend shares I’d buy today Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Image source: Getty Images. See all posts by Edward Sheldon, CFA Investing for dividends has been challenging for UK investors this year. As a result of Covid-19, over 40 companies in the FTSE 100 index have either suspended or cancelled their dividends.However, there are still plenty of UK companies paying dividends to their investors. Here’s a look at three I like the look of right now.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…A UK dividend share with a 5% dividend yieldThe first I want to highlight is healthcare giant GlaxoSmithKline (LSE: GSK). It paid out total dividends of 80p per share to investors last year, which equates to a trailing yield of around 5% at the current share price.In its recent first-quarter results, Glaxo declared a first interim dividend for 2020 of 19p per share, in line with the dividend for the same period last year. And looking ahead, the company advised it currently intends to pay out 80p per share in dividends for 2020, assuming there’s no material change in the external environment or performance expectations. This suggests GSK will continue to be a cash cow for investors.As a specialist in pharmaceuticals, vaccines, and consumer healthcare products, I think Glaxo looks well-positioned for growth in the current environment. With the stock trading on a P/E ratio less than 14 and sporting a yield of around 5%, I think it’s a good time to be buying.Powerful dividend growthSticking with the healthcare sector, I also like the look of Hikma Pharmaceuticals (LSE: HIK) right now. It’s an under-the-radar FTSE 100 healthcare company that’s focused on developing, manufacturing, and marketing branded and non-branded generic medicines.This UK dividend share doesn’t have the highest yield. Last year, the company paid out 44 cents per share which, at the current share price, equates to a trailing yield of about 1.6%. However, what stands out to me here is the growth rate of Hikma’s payout.Over the last five years, the dividend payout has doubled. You don’t see that kind of growth within the FTSE 100 index very often. Moreover, dividend coverage is very high. This suggests there could be plenty more growth to come.Hikma shares currently trade on a forward-looking P/E ratio of about 17. I see that valuation as attractive. I think this stock has the potential to deliver both capital gains and dividends.21 consecutive dividend increasesFinally, I see a lot of appeal in alcoholic beverages champion Diageo (LSE: DGE) at the moment. It paid out 68.6p in dividends last year, which translates to a trailing yield of about 2.5% at the current share price.Diageo has a superb long-term dividend growth track record. Since the company paid its first dividend back in 1998, it’s notched up 21 consecutive annual increases. There aren’t many companies that can boast that kind of impressive track record.In the short term, Diageo’s earnings are likely to take a hit due to Covid-19. However, I think it’s unlikely that the FTSE 100 company will cut its dividend. I imagine the company will do everything in its power to maintain its enviable dividend track record. Diageo is currently trading nearly 25% below its 52-week high. It’s not often you see that kind of pullback with this FTSE 100 stock. I’d buy this UK dividend stock today while it’s out of favour. I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Edward Sheldon owns shares in GlaxoSmithKline and Diageo. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Diageo and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.center_img Our 6 ‘Best Buys Now’ Shares “This Stock Could Be Like Buying Amazon in 1997” Edward Sheldon, CFA | Friday, 10th July, 2020 | More on: DGE GSK HIK I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Simply click below to discover how you can take advantage of this. Enter Your Email Addresslast_img

Leave a Reply

Your email address will not be published. Required fields are marked *